1. Home
  2. FRD vs MGNX Comparison

FRD vs MGNX Comparison

Compare FRD & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Friedman Industries Inc.

FRD

Friedman Industries Inc.

HOLD

Current Price

$18.33

Market Cap

134.3M

Sector

Industrials

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.73

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRD
MGNX
Founded
1965
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.3M
115.8M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
FRD
MGNX
Price
$18.33
$1.73
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.20
AVG Volume (30 Days)
21.8K
546.8K
Earning Date
05-18-2026
01-01-0001
Dividend Yield
0.89%
N/A
EPS Growth
N/A
N/A
EPS
1.46
N/A
Revenue
$121,157,278.00
$149,962,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.64
N/A
Revenue Growth
55.82
155.26
52 Week Low
$12.24
$0.99
52 Week High
$24.37
$2.63

Technical Indicators

Market Signals
Indicator
FRD
MGNX
Relative Strength Index (RSI) 41.70 42.87
Support Level $18.54 $1.57
Resistance Level $20.60 $1.70
Average True Range (ATR) 1.19 0.07
MACD -0.19 -0.01
Stochastic Oscillator 12.89 22.68

Price Performance

Historical Comparison
FRD
MGNX

About FRD Friedman Industries Inc.

Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: